Understanding how lupus affects heart health
Official title: Defining the Regulatory Landscape of Lupus with CVD Comorbidity
Funded at Oklahoma Medical Research Foundation · NIH-11073626 · Data updated 2026-11-12
This study is looking at how lupus affects heart health and aims to find out if certain genes play a role in making lupus worse, which could help doctors give better diagnoses and treatments for people with lupus and heart issues.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oklahoma Medical Research Foundation NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project start | November 20, 2024 |
| Project end | October 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $793,093 |
| NIH project number | 1R01AI183676-01A1 |
| Project ID | NIH-11073626 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with systemic lupus erythematosus, particularly those experiencing cardiovascular issues.
✕Less likely to help
Patients without a diagnosis of lupus or those not experiencing cardiovascular complications may not benefit from this research.
What this research studies
This research investigates the complex relationship between systemic lupus erythematosus (SLE) and cardiovascular diseases (CVD). It aims to identify genetic factors that contribute to the severity of lupus and its impact on heart health. By studying immune cells and their genetic makeup, the research seeks to uncover how certain genetic variations influence the behavior of these cells in the context of lupus and CVD. This could lead to more accurate diagnoses and personalized treatment options for patients.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnosis and treatment strategies for patients with lupus and cardiovascular complications.
How similar studies have gone: Previous research has shown promise in understanding genetic factors in autoimmune diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Oklahoma Medical Research Foundation
Oklahoma City, United States Active
Researchers
- Principal investigator: Nath, Swapan K. — Oklahoma Medical Research Foundation
- Study coordinator: Nath, Swapan K.
Related research
Other NIH-funded projects on the same topics.
-
Understanding how DIS3L2 helps keep RNA in check to help lupus patients
A physician-scientist team is studying how a watchdog molecule for RNA (DIS3L2) may drive lupus-related immune problems, with the goal of uncovering new paths to treatment.
-
Pathogenic T cells in discoid lupus erythematosus
A doctor-scientist at Yale is studying why certain immune T cells cause skin damage in discoid lupus, with the goal of finding ways to reduce scarring and improve health for patients, especially African American women.
-
Glycoprotein urine markers that signal lupus nephritis treatment response
A novel test uses urine glycoprotein patterns to show how well lupus nephritis is responding to standard treatment.
-
Immunostimulatory short non-coding RNAs and lupus
A study in people with lupus looks at tiny RNA pieces that may spark inflammation, to understand if they drive disease activity.
-
Antiviral factors that limit HIV in people with SLE
Researchers at Howard University are studying how immune factors in people with lupus may help limit HIV infection.
-
PTPRS and lupus nephritis: a new target to reduce kidney damage in lupus
Aims to understand how PTPRS contributes to kidney inflammation and scarring in lupus nephritis and explore targeting it to help patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.